Insights

Cutting-Edge Immunotherapies OncoResponse is a biotech company developing innovative cancer immunotherapies leveraging insights from elite cancer responders. The lead candidate, OR2805, offers a transformative approach to cancer therapeutics, making it a compelling solution for healthcare providers seeking advanced treatment options.

High-Profile Collaborations Through strategic alliances with renowned institutions like MD Anderson Cancer Center and Regeneron, OncoResponse has established credibility in the immuno-oncology space. This opens up opportunities for partnerships with hospitals and research facilities interested in cutting-edge therapies and collaborations with industry leaders.

Renowned Key Personnel OncoResponse boasts a strong leadership team, including experts like Miriam Merad and Carol Gallagher, known for their contributions to the field of immunotherapy. Leveraging the expertise and reputation of such key personnel can enhance the company's credibility and attract collaborations with organizations valuing top talent.

Financial Support and Grants Securing funding and grants, such as the $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT), demonstrates financial stability and recognition of OncoResponse's potential. This financial backing can serve as a strong selling point when pitching to investors or partners looking to support innovative cancer research.

Expansion Through New Antibodies OncoResponse's recent launch of OR502 anti-LILRB2 antibody and OR641 dual anti-LILRB2/1 antibody presents new sales opportunities. These novel therapies highlight the company's continuous innovation and can be attractive to healthcare providers seeking to offer their patients cutting-edge immunotherapies for cancer treatment.

Similar companies to OncoResponse

RXi Pharmaceuticals Corporation
11$10M

OncoResponse Tech Stack

OncoResponse uses 8 technology products and services including jsDelivr, WordPress, Mailchimp, and more. Explore OncoResponse's tech stack below.

jsDelivr
Content Delivery Network
WordPress
Content Management System
Mailchimp
Email
Open Graph
Miscellaneous
Amazon Web Services
Platform As A Service
Ruby
Programming Languages
Ruby on Rails
Web Frameworks
OpenResty
Web Servers

Media & News

OncoResponse's Email Address Formats

OncoResponse uses at least 2 format(s):

OncoResponse Email Formats	Example	Percentage
FLast@oncoresponseinc.com	JDoe@oncoresponseinc.com	98%
LFirst@oncoresponseinc.com	DJohn@oncoresponseinc.com	2%
FLast@oncoresponse.com	JDoe@oncoresponse.com	100%

Frequently Asked Questions

Where is OncoResponse's headquarters located?

OncoResponse's main headquarters is located at 609 Main Street Suite 4200 Houston, Texas 77002 US. The company has employees across 2 continents, including North AmericaAsia.

What is OncoResponse's official website and social media links?

OncoResponse's official website is oncoresponse.com and has social profiles on LinkedIn.

How much revenue does OncoResponse generate?

As of May 2024, OncoResponse's annual revenue reached $1.8M.

What is OncoResponse's NAICS code?

OncoResponse's NAICS code is 5417 - Scientific Research and Development Services.

How many employees does OncoResponse have currently?

As of May 2024, OncoResponse has approximately 16 employees across 2 continents, including North AmericaAsia. Key team members include Chief Financial Officer: C. R.Director Of Research & Early Development: M. B.Senior Director Immuno-Oncology: P. P.. Explore OncoResponse's employee directory with LeadIQ.

What industry does OncoResponse belong to?

OncoResponse operates in the Research Services industry.

What technology does OncoResponse use?

OncoResponse's tech stack includes jsDelivrWordPressMailchimpOpen GraphAmazon Web ServicesRubyRuby on RailsOpenResty.

What is OncoResponse's email format?

OncoResponse's email format typically follows the pattern of . Find more OncoResponse email formats with LeadIQ.

When was OncoResponse founded?

OncoResponse was founded in 2016.

OncoResponse

Research ServicesTexas, United States11-50 Employees

OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lead candidate, OR2805, has entered clinical studies with a unique and transformative approach to the advancement of cancer therapeutics. 

OncoResponse is based in Houston, Texas and Seattle, Washington.

Company Overview

Headquarters: 609 Main Street Suite 4200 Houston, Texas 77002 US
Website: oncoresponse.com
NAICS Code: 5417 - Scientific Research and Development Services
Founded: 2016
Employees: 11-50

Media & News

Funding & Financials

$10M
OncoResponse's revenue is in the range of $10M

Funding & Financials

$10M
OncoResponse's revenue is in the range of $10M

Company Leadership

C. R.
Chief Financial Officer
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. B.
Director Of Research & Early Development
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
P. P.
Senior Director Immuno-Oncology
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
R. M.
Director Of Fp&a
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
T. F.
Associate Director, Cmc
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

A. F.
Project Manager
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
C. S.
Senior Marketing Consultant
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. S.
Scientist Ii
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
G. N.
Scientist Ii
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. W.
Associate Scientist
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for OncoResponse and Millions of Other Companies
Sign up for full access to OncoResponse information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to OncoResponse

RXi Pharmaceuticals Corporation

OncoResponse Tech Stack

Media & News

OncoResponse, Inc. launches OR502 anti-LILRB2 antibody and OR641 dual anti-LILRB2/1 antibody.

OncoResponse, Inc. hired Carol Gallagher as Board of Directors on Sep 6th '23.

OncoResponse, Inc. receives financing of $13M in grant.

OncoResponse, Inc. partnered with MD Anderson Cancer Center on Aug 2nd '22.

OncoResponse, Inc. partnered with Regeneron on Sep 7th '22.

OncoResponse, Inc. hired Miriam Merad as MD on Nov 9th '21.

OncoResponse, Inc. hired Sean A. McCarthy as Independent Director to Board of Directors on Jul 7th '21.

OncoResponse's Email Address Formats

Frequently Asked Questions

Where is OncoResponse's headquarters located?

What is OncoResponse's official website and social media links?

How much revenue does OncoResponse generate?

What is OncoResponse's NAICS code?

How many employees does OncoResponse have currently?

What industry does OncoResponse belong to?

What technology does OncoResponse use?

What is OncoResponse's email format?

When was OncoResponse founded?

OncoResponse

Company Overview

Media & News

OncoResponse, Inc. launches OR502 anti-LILRB2 antibody and OR641 dual anti-LILRB2/1 antibody.

OncoResponse, Inc. hired Carol Gallagher as Board of Directors on Sep 6th '23.

OncoResponse, Inc. receives financing of $13M in grant.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?